Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘PI3K’

AACR 2013 GDC-0032 a next generation PI3K Inhibitor shows early promise in breast cancer

By on April 8, 2013

Genentech’s next generation PI3-kinase inhibitor, GDC-0032, was the topic of two presentations yesterday at the 2013 annual meeting of the American Association for Cancer Research (AACR) taking place in Washington D.C.

Genentech have put substantial resources into developing new agents that target different elements of the PI3K pathway.  These include: GDC-0941, GDC-0980, GDC-0084, GDC-0349, GDC-0068.  At this year’s AACR, data on their latest compound, GDC-0032, was presented. This agent is a selective inhibitor of PI3K alpha, delta and gamma but spares inhibition of the PI3K-beta isoform.

This is a preview of AACR 2013 GDC-0032 a next generation PI3K Inhibitor shows early promise in breast cancer. Read the full post

Leave a comment

Which posters were hot at ASH 2011?

By on December 16, 2011

In my final post about the 2011 American Society of Hematology (ASH) annual meeting, I want to highlight a few of the 4000+ posters that appeared to attract a lot of interest.

ASH 2011 Poster Viewing 300x225 Which posters were hot at ASH 2011?The three ASH poster sessions in the equivalent of an aircraft hangar, had a lot of interesting science and clinical data.

All the posters had merit in order to be selected for publication, so my selection is entirely subjective:

Bruton’s Tyrosine Kinase (BTK)

Two posters on products targeting BTK attracted a lot of traffic:

#3485 Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the treatment of B Cell malignancies 

This is a preview of Which posters were hot at ASH 2011?. Read the full post

Leave a comment

Gilead acquires Calistoga and CAL-101 for $375M

By on February 22, 2011

Gilead Sciences Logo 300x120 Gilead acquires Calistoga and CAL 101 for $375M

In an acquisition that highlights the importance of cancer and inflammation, Gilead Sciences today announced the acquisition of Seattle based Calistoga Pharmaceuticals for $375M.

Calistoga’s pipeline is focused on the development of PI3 kinase inhibitors for cancer and inflammation. Sally Church on Pharma Strategy Blog has written extensively about “The potential of the PI3K pathway inhibitors in lung cancer”, and discussed Calistoga’s CAL-101 compound and its development for hematological malignancies in her report on “What’s hot at ASH in 2010”.

This is a preview of Gilead acquires Calistoga and CAL-101 for $375M. Read the full post

1 Comment